Novartis AG
Novartis AG NVS Peers
See (NVS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVS | $121.01 | +0.83% | 239B | 18.97 | $6.38 | +3.30% |
| LLY | $779.53 | +0.53% | 738.8B | 63.64 | $12.25 | +0.72% |
| AZN | $69.88 | +0.04% | 433.3B | 28.18 | $2.48 | +2.21% |
| JNJ | $152.75 | +0.22% | 367.4B | 16.99 | $8.99 | +3.31% |
| ABBV | $185.62 | +1.82% | 327.8B | 79.64 | $2.33 | +3.45% |
| NVO | $69.02 | +0.74% | 305.6B | 19.02 | $3.63 | +2.34% |
| MRK | $79.16 | +0.08% | 198.7B | 11.50 | $6.88 | +4.05% |
| AMGN | $279.21 | +0.75% | 150.1B | 25.43 | $10.98 | +3.34% |
| GILD | $110.87 | +0.18% | 137.9B | 14.32 | $7.74 | +2.83% |
| PFE | $24.24 | +0.21% | 137.8B | 17.57 | $1.38 | +7.03% |
Stock Comparison
NVS vs LLY Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, LLY has a market cap of 738.8B. Regarding current trading prices, NVS is priced at $121.01, while LLY trades at $779.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas LLY's P/E ratio is 63.64. In terms of profitability, NVS's ROE is +0.31%, compared to LLY's ROE of +0.77%. Regarding short-term risk, NVS is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs AZN Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, AZN has a market cap of 433.3B. Regarding current trading prices, NVS is priced at $121.01, while AZN trades at $69.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas AZN's P/E ratio is 28.18. In terms of profitability, NVS's ROE is +0.31%, compared to AZN's ROE of +0.19%. Regarding short-term risk, NVS is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.
NVS vs JNJ Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, JNJ has a market cap of 367.4B. Regarding current trading prices, NVS is priced at $121.01, while JNJ trades at $152.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas JNJ's P/E ratio is 16.99. In terms of profitability, NVS's ROE is +0.31%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, NVS is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.
NVS vs ABBV Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, ABBV has a market cap of 327.8B. Regarding current trading prices, NVS is priced at $121.01, while ABBV trades at $185.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas ABBV's P/E ratio is 79.64. In terms of profitability, NVS's ROE is +0.31%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, NVS is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs NVO Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, NVO has a market cap of 305.6B. Regarding current trading prices, NVS is priced at $121.01, while NVO trades at $69.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas NVO's P/E ratio is 19.02. In terms of profitability, NVS's ROE is +0.31%, compared to NVO's ROE of +0.81%. Regarding short-term risk, NVS is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs MRK Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, MRK has a market cap of 198.7B. Regarding current trading prices, NVS is priced at $121.01, while MRK trades at $79.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas MRK's P/E ratio is 11.50. In terms of profitability, NVS's ROE is +0.31%, compared to MRK's ROE of +0.38%. Regarding short-term risk, NVS is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs AMGN Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, AMGN has a market cap of 150.1B. Regarding current trading prices, NVS is priced at $121.01, while AMGN trades at $279.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas AMGN's P/E ratio is 25.43. In terms of profitability, NVS's ROE is +0.31%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, NVS is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs GILD Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, GILD has a market cap of 137.9B. Regarding current trading prices, NVS is priced at $121.01, while GILD trades at $110.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas GILD's P/E ratio is 14.32. In terms of profitability, NVS's ROE is +0.31%, compared to GILD's ROE of +0.32%. Regarding short-term risk, NVS is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs PFE Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, PFE has a market cap of 137.8B. Regarding current trading prices, NVS is priced at $121.01, while PFE trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas PFE's P/E ratio is 17.57. In terms of profitability, NVS's ROE is +0.31%, compared to PFE's ROE of +0.09%. Regarding short-term risk, NVS is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs SNY Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, SNY has a market cap of 117.7B. Regarding current trading prices, NVS is priced at $121.01, while SNY trades at $48.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas SNY's P/E ratio is 16.66. In terms of profitability, NVS's ROE is +0.31%, compared to SNY's ROE of +0.08%. Regarding short-term risk, NVS is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs BMY Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, BMY has a market cap of 94.2B. Regarding current trading prices, NVS is priced at $121.01, while BMY trades at $46.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas BMY's P/E ratio is 17.27. In terms of profitability, NVS's ROE is +0.31%, compared to BMY's ROE of +0.32%. Regarding short-term risk, NVS is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs CELG-RI Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, CELG-RI has a market cap of 84.1B. Regarding current trading prices, NVS is priced at $121.01, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.31%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, NVS is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs GSK Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, GSK has a market cap of 78.6B. Regarding current trading prices, NVS is priced at $121.01, while GSK trades at $38.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas GSK's P/E ratio is 18.82. In terms of profitability, NVS's ROE is +0.31%, compared to GSK's ROE of +0.22%. Regarding short-term risk, NVS is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs HZNP Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVS is priced at $121.01, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVS's ROE is +0.31%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVS is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.
NVS vs BIIB Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, BIIB has a market cap of 18.4B. Regarding current trading prices, NVS is priced at $121.01, while BIIB trades at $125.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas BIIB's P/E ratio is 12.41. In terms of profitability, NVS's ROE is +0.31%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, NVS is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs GRFS Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, GRFS has a market cap of 7.5B. Regarding current trading prices, NVS is priced at $121.01, while GRFS trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas GRFS's P/E ratio is 33.48. In terms of profitability, NVS's ROE is +0.31%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, NVS is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs OGN Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, OGN has a market cap of 2.5B. Regarding current trading prices, NVS is priced at $121.01, while OGN trades at $9.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas OGN's P/E ratio is 3.36. In terms of profitability, NVS's ROE is +0.31%, compared to OGN's ROE of +1.82%. Regarding short-term risk, NVS is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs CTOR Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, CTOR has a market cap of 311.3M. Regarding current trading prices, NVS is priced at $121.01, while CTOR trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas CTOR's P/E ratio is -11.45. In terms of profitability, NVS's ROE is +0.31%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, NVS is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs SCLX Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, SCLX has a market cap of 40.9M. Regarding current trading prices, NVS is priced at $121.01, while SCLX trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas SCLX's P/E ratio is -0.39. In terms of profitability, NVS's ROE is +0.31%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, NVS is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs SCLXW Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, SCLXW has a market cap of 36.3M. Regarding current trading prices, NVS is priced at $121.01, while SCLXW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.31%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, NVS is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs MIRA Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, MIRA has a market cap of 21M. Regarding current trading prices, NVS is priced at $121.01, while MIRA trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas MIRA's P/E ratio is -2.57. In terms of profitability, NVS's ROE is +0.31%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, NVS is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs SRXH Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, SRXH has a market cap of 6.8M. Regarding current trading prices, NVS is priced at $121.01, while SRXH trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas SRXH's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.31%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, NVS is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs CRXT Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 239B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVS is priced at $121.01, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 18.97, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVS's ROE is +0.31%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVS is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.